Interested in sharing the research? You can order print copies of many research publications.

Order Reprints

Newsletter Sign-Up

Keep up to date with NPC news and events by signing up for our e-newsletter E.V.I.dently, and our CER Daily Newsfeed.

Subscribe POLICY

The State of Comparative Effectiveness Research and the Environment for Health Care Decision Making (2012)

In its second annual survey of key health care stakeholders, NPC, working with the public health research firm Social & Scientific Systems (SSS), examined the environment for health care decisions, especially the current state of CER and its impact on medical decision making.

The purpose was to set a baseline for where key stakeholders believe we are today on CER and for tracking progress and judging future effects. According to the findings, there is clear recognition among key health care influentials about the importance of CER and its promise for the future. These stakeholders also expressed tempered optimism about progress in efforts to provide or improve the tools necessary for this research, and that any significant effects of CER are yet to be realized, and much work remains to be done.

CER Survey Highlights:

In its second survey to gauge attitudes around comparative effectiveness research (CER), the National Pharmaceutical Council was able to capture shifts in the conversation. 

CER continues to be a key issue of importance to stakeholders, but perceived importance has leveled off between 2011 and 2012.

  • More than half (53 percent) of survey respondents were “very familiar” with comparative effectiveness research and one-third of respondents were “somewhat familiar” with CER.
  • Of survey respondents, 95 percent said that CER was “somewhat” or “very important” to them or their organizations, a small increase from the 91 percent cited a year earlier.
  • However, the percentage that said CER was very important was lower than in the previous survey, declining from 71 percent to 64 percent. 

The Patient Centered Outcomes Research Institute (PCORI) continues to be recognized as an important player in CER.

  • Audiences who were “somewhat” to “very” familiar with PCORI rose by 8 percent over last year, increasing from 70 percent to 78 percent.
  • Between the 2011 survey and the 2012, PCORI showed the biggest jumps in recognition in key areas, compared to other organizations including the Agency for Healthcare Research and Quality (AHRQ), National Institutes of Health (NIH), Food and Drug Administration (FDA), private payers, academia and pharmaceutical industry. 
  • Stakeholders’ expectations of PCORI’s influence jumped most dramatically in two areas:
    • Establishing research standards – from 50 percent to 72 percent
    • Funding and monitoring research – from 44 percent to 60 percent

However, in key areas of importance, PCORI has yet to assume a leadership position among stakeholders. Survey respondents ranked who they thought would be the most important influencers in the next five years within these areas:

Who will help establish research standards around CER?

  1. AHRQ (83 percent)
  2. PCORI (72 percent)
  3. NIH (60 percent)

Who will establish research priorities?

  1. AHRQ (77 percent)
  2. NIH (71 percent)
  3. PCORI (67 percent)

Who will fund and monitor research?

  1. NIH (85 percent)
  2. AHRQ (74 percent)
  3. Pharmaceutical Medical Products Industry (66 percent)

(PCORI was rated 60 percent)

Who will conduct comparative effectiveness research?

  1. Academia (88 percent)
  2. Pharmaceutical Medical Products Industry (70 percent)
  3. NIH (50 percent)

Expectations are still strong that CER will improve health care decision-making, but few expect that impact to be felt soon.

  • In the next year, only 30 percent of respondents felt CER would moderately or substantially improve health care decision-making
  • In the next three years, 77 percent expected improvement
  • In the next five years, 91 percent expected improvement

CER Survey Parameters:

The survey, conducted from October 2011-February 2012, targeted key stakeholders who have an impact on, or are affected by, research involving medical effectiveness, including researchers/thought leaders; government; insurers and health plans; employers; business coalitions/HR specialists; and associations/trade groups. A total of 117 stakeholders participated.

Survey materials:

Newsletter Volume

E.V.I.dently January 2015

NPC MessageHealth Care Outlook for 2015In this month’s Message from NPC, President Dan Leonard considers how the Affordable Care Act and stakeholders...
Blog Post

CER Tweets of the Week: New UMB Center of Excellence In CER, UIC College of Pharmacy Master’s in CER, PCORI in Lancet (January 19-23)

Comparative effectiveness research (CER) stakeholders tweeted about new educational opportunities regarding CER. They shared an announcement about a...
Blog Post

CER Tweets of the Week: The Challenges of Gray-Zone Medicine, PCORI in the Congress Blog (January 12-16)

This week, comparative effectiveness research (CER) stakeholders tweeted multiple articles regarding CER and various challenges they face. They...
Blog Post

CER Tweets of the Week: AcademyHealth Compares International CER, Resource Library on CER (January 5-9)

This week, comparative effectiveness research (CER) stakeholders tweeted about @AcademyHealth’s new paper comparing international efforts to boost...
Press Release

NPC Study Outlines When & How Health Decision-Makers Should Consider Individual Patient Differences

Washington, DC (July 29, 2014)—New research led by the National Pharmaceutical Council (NPC) can assist health care stakeholders to understand when...
Press Release

NPC Annual Stakeholder Survey: Comparative Effectiveness Research Is Important, But Impact on Health Care Decision-Making Is Still on the Horizon

(Washington, DC, May 19, 2014)—A new survey of health care stakeholders reveals continued optimism for the use of comparative effectiveness research...
Press Release

CER Collaborative Improving Health Outcomes Through New Comparative Evidence Tools

(Washington, DC, March 24, 2014)—Three peer-reviewed articles published in Value in Health offer important guidance to aid formulary decision-makers...
Press Release

NPC, UMD Study: Factors That Cause Different Treatment Responses Are Not Well Understood or Studied

Washington, DC, November 4, 2013—Although researchers and health care providers widely recognize that individuals with stage IV prostate cancer react...
Commentary and Testimony Page

NPC Comments on PCORI Proposal for Peer Review of Primary Research and Public Release of Research Findings

November 7, 2014Dr. Joe SelbyExecutive DirectorPatient-Centered Outcomes Research Institute1828 L St., NW, Suite 900Washington, DC 20036Dear Dr....
Commentary and Testimony Page

The State of CER and the Environment for Health Care Decision Making

This month, NPC released its third annual survey on stakeholders’ views on comparative effectiveness research (CER), “The State of Comparative...
Commentary and Testimony Page

Keeping Our Eye on the CER Ball

Until the cherry blossoms begin to bloom later next month, most of the water cooler conversations in Washington will focus on the federal budget....
Commentary and Testimony Page

Leveling the Playing Field? Could a Landmark Decision Alter the CER Communications Landscape?

A growing chorus of voices is publicly sharing data on the effectiveness of treatment options, but one viewpoint has long been shut out of key areas...
YouTube Videos

Real-World Impact of Comparative Effectiveness Research Findings on Clinical Practice

National Pharmaceutical Council Chief Science Officer Robert W. Dubois, MD, PhD, discusses a peer-reviewed study suggesting that changes are needed...
YouTube Videos

CER and the Environment for Health Care Decision-Making

The National Pharmaceutical Council’s (NPC) fourth annual survey of health care stakeholders is continuing to shed light on the current environment...
YouTube Videos

Webinar: CER Collaborative: Tools You Can Use

Collaborative members hosted a webinar explaining how to use the tools they developed to create greater uniformity and transparency when evaluating...
YouTube Videos

Patient Input on What Makes Comparative Effectiveness Research Useful

Myrl Weinberg, chief executive officer of the National Health Council, says that many patients are still concerned about how comparative...
Blog Post

CER Tweets of the Week: New UMB Center of Excellence In CER, UIC College of Pharmacy Master’s in CER, PCORI in Lancet (January 19-23)

Comparative effectiveness research (CER) stakeholders tweeted about new educational opportunities regarding CER. They shared an announcement about a...
Blog Post

CER Tweets of the Week: The Challenges of Gray-Zone Medicine, PCORI in the Congress Blog (January 12-16)

This week, comparative effectiveness research (CER) stakeholders tweeted multiple articles regarding CER and various challenges they face. They...
Blog Post

CER Tweets of the Week: AcademyHealth Compares International CER, Resource Library on CER (January 5-9)

This week, comparative effectiveness research (CER) stakeholders tweeted about @AcademyHealth’s new paper comparing international efforts to boost...
Blog Post

CER Tweets of the Week: Clinical Uncertainty in Surgery and EBM & Patient-Centered Medicine and EBM (December 29 – January 2)

This week, articles about evidence-based medicine (EBM) attracted the attention of comparative effectiveness research (CER) stakeholders on Twitter....

Research

  •  
  • 1 of 11
  • >

Commentary & Testimony